Cargando…

Cognitive functioning and depressive symptoms in Fabry disease: A follow‐up study

Patients with Fabry disease (FD) have a high prevalence of depressive symptoms and can suffer from cognitive impairment, negatively affecting their life. The course of cognitive functioning and depressive symptoms in FD is unknown. The aim of this prospective cohort study was to describe changes in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Körver, Simon, Geurtsen, Gert J., Hollak, Carla E. M., van Schaik, Ivo N., Longo, Maria G. F., Lima, Marjana R., Dijkgraaf, Marcel G. W., Langeveld, Mirjam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540266/ https://www.ncbi.nlm.nih.gov/pubmed/32510623 http://dx.doi.org/10.1002/jimd.12271

Ejemplares similares

Depressive symptoms in Fabry disease: the importance of coping, subjective health perception and pain
por: Körver, Simon, et al.
Publicado: (2020)

Predictors of objective cognitive impairment and subjective cognitive complaints in patients with Fabry disease
por: Körver, Simon, et al.
Publicado: (2019)

The Mini Mental State Examination does not accurately screen for objective cognitive impairment in Fabry Disease
por: Körver, Simon, et al.
Publicado: (2019)

Developments in the treatment of Fabry disease
por: van der Veen, Sanne J., et al.
Publicado: (2020)

Cost-effectiveness of enzyme replacement therapy for Fabry disease
por: Rombach, Saskia M, et al.
Publicado: (2013)

Influence of sex and phenotype on cardiac outcomes in patients with Fabry disease
por: El Sayed, Mohamed, et al.
Publicado: (2021)

Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests
por: Biegstraaten, Marieke, et al.
Publicado: (2010)

Poikilothermia in a 38-year-old Fabry patient
por: Biegstraaten, Marieke, et al.
Publicado: (2010)

Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease
por: van der Veen, Sanne J., et al.
Publicado: (2020)

Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
por: Rombach, Saskia M, et al.
Publicado: (2013)

Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study
por: Arends, Maarten, et al.
Publicado: (2017)

Pain management strategies for neuropathic pain in Fabry disease - a systematic review
por: Schuller, Y., et al.
Publicado: (2016)

Prevalence of symptoms in female Fabry disease patients: a case-control survey
por: Bouwman, Machtelt G., et al.
Publicado: (2012)

Erratum to: Pain management strategies for neuropathic pain in Fabry disease - a systematic review
por: Schuller, Y., et al.
Publicado: (2016)

ECG Changes during Adult Life in Fabry Disease: Results from a Large Longitudinal Cohort Study
por: El Sayed, Mohamed, et al.
Publicado: (2023)

Quality of life in patients with Fabry disease: a systematic review of the literature
por: Arends, Maarten, et al.
Publicado: (2015)

Antibodies against recombinant enzyme in the treatment of Fabry disease: Now you see them, now you don’t
por: van der Veen, Sanne Jolien, et al.
Publicado: (2022)

Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease
por: van Dussen, Laura, et al.
Publicado: (2014)

Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications
por: van Dussen, Laura, et al.
Publicado: (2014)

Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease
por: Shu, Liming, et al.
Publicado: (2014)

Effectiveness of cognitive remediation in depression: a meta-analysis
por: Legemaat, Amanda M., et al.
Publicado: (2022)

Bone health in patients with inborn errors of metabolism
por: Langeveld, M., et al.
Publicado: (2018)

Gastrointestinal Symptoms of Patients with Fabry Disease
por: Pensabene, Licia, et al.
Publicado: (2016)

Eight-Year Follow-Up of Neuropsychiatric Symptoms and Brain Structural Changes in Fabry Disease
por: Lelieveld, Irene M., et al.
Publicado: (2015)

Renal involvement in a patient with the chronic visceral subtype of acid sphingomyelinase deficiency resembles Fabry disease
por: Eskes, Eline C. B., et al.
Publicado: (2021)

Recurrent metabolic alkalosis following ketone body treatment of adult mitochondrial trifunctional protein deficiency: A case report
por: Stolwijk, Nina N., et al.
Publicado: (2022)

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients
por: Smid, Bouwien E, et al.
Publicado: (2011)

The challenges of classical galactosemia: HRQoL in pediatric and adult patients
por: Hermans, Merel E., et al.
Publicado: (2023)

The cognitive profile of type 1 Gaucher disease patients
por: Biegstraaten, Marieke, et al.
Publicado: (2012)

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
por: Arends, Maarten, et al.
Publicado: (2018)

Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg
por: Vedder, Anouk C., et al.
Publicado: (2007)

Fabry disease: a survey of visual and ocular symptoms
por: Davey, Pinakin Gunvant
Publicado: (2014)

Genetic variants associated with gastrointestinal symptoms in Fabry disease
por: Di Martino, Maria Teresa, et al.
Publicado: (2016)

Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation
por: van Kuilenburg, André B. P., et al.
Publicado: (2023)

Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors
por: Arends, Maarten, et al.
Publicado: (2017)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Registries for orphan drugs: generating evidence or marketing tools?
por: Hollak, Carla E. M., et al.
Publicado: (2020)

Fabry-Perot interferometers
por: Mora-Hernandez, G
Publicado: (1988)

Excessive Daytime Sleepiness Is a Common Symptom in Fabry Disease
por: Duning, Thomas, et al.
Publicado: (2009)

Recurrent fever of unknown origin: An overlooked symptom of Fabry disease
por: Luo, Yi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_purbmj7v5uo6bbft9282ba8ao9